RFK Jr. lets pharmacies sell six peptides, overruling FDA scientists

HHS Secretary Robert F. Kennedy Jr. issued an enforcement-discretion policy allowing compounding pharmacies to make and sell BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. The FDA had removed the peptides over insufficient evidence of efficacy and safety concerns.

• Rule published in the Federal Register on October 30 leaves the peptides' regulatory status unchanged
• HHS will not take enforcement action against pharmacies compounding the six peptides
• An FDA advisory panel voted in July to restore the peptides after Kennedy replaced 8 of 12 members
• Critics cite already reported harms and lack of human trials